switching from tirzepatide to semaglutide dosage chart Guide In 2026 Switching From Tirzepatide to Semaglutide:

If tolerated, we may go up in the dose

In the ACHIEVE-2 trial (Phase 3, 962 adults with type 2 diabetes on metformin), Orforglipron, a novel small-molecule oral GLP-1 RA went head-to-head against Dapagliflozin, one of the most widely used SGLT2 inhibitors

In the Phase 3 TRIUMPH-1 trial reported May 21, 2026, the 12 mg arm produced mean body-weight reduction of 28.3% at 80 weeks, with extension data reaching 30.3% at 104 weeks [1][2]

Your doctor can help you transition to appropriate diabetes or weight management strategies that are safe during pregnancy planning and can ensure your contraceptive method is appropriate during this transition period

Targeted by Tirzepatide and Retatrutide